Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHair loss during Mounjaro treatment is real, and it affects a meaningful proportion of people who use it. It has a name (telogen effluvium) and a clear biological explanation rooted in rapid weight loss rather than the medicine itself. Understanding why it happens, and whether it is likely to be permanent, is the most useful thing to know before making a decision about how to respond. Mounjaro (tirzepatide) is a prescription-only medicine that requires clinical assessment before a prescriber can recommend it.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A common misconception is that tirzepatide is chemically stripping the hair from follicles. That is not what happens. The mechanism is almost certainly telogen effluvium: a well-understood response in which physical or metabolic stress pushes a larger-than-normal proportion of hair follicles into their resting phase simultaneously. When those follicles shed, weeks or months later, the result is noticeable thinning across the scalp rather than patchy bald spots.
Rapid weight loss is one of the most reliably documented triggers for this process. The same pattern appears in people recovering from surgery, severe illness, or crash dieting, the cause is the sudden calorie deficit and its downstream effects on protein availability and metabolic signalling, not the specific route taken to get there. Mounjaro works partly by reducing appetite substantially, which means people lose weight quickly. That speed of loss is a feature in terms of metabolic health; it also happens to be the driver of the hair shedding some people experience.
The NHS medicines page for tirzepatide lists alopecia as an uncommon side effect. "Uncommon" in pharmacovigilance language means it affects somewhere between one in a hundred and one in a thousand people in formal trial conditions. Real-world reports, however, tend to come in higher numbers, consistent with the idea that the mechanism is nutritional and metabolic rather than a direct pharmacological effect of the drug molecule.
Not everyone on Mounjaro loses noticeable amounts of hair. Several factors appear to raise the likelihood. Losing weight quickly, eating substantially less protein than usual, having had any previous period of significant hair thinning, and being generally under high physiological stress all tip the balance. Women tend to notice it more acutely because female hair loss is more visible at the temples and parting.
Timing is important too. Telogen effluvium does not appear during the first few weeks of treatment. There is a lag (typically two to four months after the trigger event) before the resting hairs shed. That delay means many people have already settled into their titration schedule by the time shedding starts, and it can feel alarming precisely because there is no obvious immediate cause. If you have recently increased your dose and weight loss has accelerated, that timing correlation is worth noting. More detail on how shedding tends to progress through a treatment course can help put the timeline into perspective.
It is also worth knowing that the pattern of loss with telogen effluvium looks different from other causes of hair thinning. Diffuse shedding across the whole scalp, visible in the shower drain or on a hairbrush rather than bald patches, is the typical picture. If you are noticing patches, or shedding that began long before any weight change, a GP or dermatologist is the right starting point, those presentations warrant separate investigation.
The most evidence-backed approach is protein intake. Hair is largely made of keratin, and keratin synthesis requires adequate dietary protein. When calorie intake falls sharply, protein is often the first casualty. Aiming for a reasonable daily protein target is something your prescriber or a registered dietitian can advise on specifically for your situation, there is no single number that applies to everyone, and the right amount depends on your weight, activity level, and how your body is responding to treatment.
Adequate micronutrient status matters too. Iron, zinc, biotin and vitamin D deficiencies are each linked to hair shedding independently, and they can all be pulled lower by reduced food intake. A blood test through your GP can identify any specific gaps worth addressing. The relationship between Mounjaro and hair and scalp changes covers some of the micronutrient detail that often gets missed in brief clinical consultations.
The good news (and it is genuine good news) is that telogen effluvium is self-limiting. Follicles are not destroyed; they are temporarily dormant. Regrowth typically begins within three to six months of the trigger period, and in most cases progresses back to close to baseline density over the following six to twelve months. Patience and nutritional support are more useful than most of the supplements marketed to people in this situation. For a broader look at this question from a different angle, the evidence overview on Mounjaro and hair is a useful companion read.
Hair loss is a legitimate clinical concern, not a vanity one, and it is worth raising at your next clinical review rather than quietly stopping treatment. Stopping abruptly to protect your hair risks a different set of problems: weight regain typically resumes without continued treatment, and any physical stress from stopping can itself trigger another bout of telogen effluvium. The decision to continue, adjust pace, or pause should be made with a prescriber who knows your full picture.
At a clinical review, a prescriber can look at whether your current titration pace is matched to your nutritional situation, whether a blood test for common deficiencies makes sense, and whether the shedding pattern fits the telogen effluvium picture or warrants a different investigation. The full Mounjaro overview covers the broader clinical context, including the eligibility criteria and what the prescribing process involves. If you have specific questions about hair changes you are not yet on treatment, our frequently asked questions page addresses several common concerns.
For anyone comparing costs or wondering whether this is the right time to start, what Mounjaro costs in the UK lays out the price landscape honestly, including what a legitimate private prescription should include. When you are ready to talk through your situation with a prescriber, check your eligibility with our clinical team, a real clinician reads every consultation, and there is no obligation to proceed.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.